Parkinsons Disease Pipeline Insights

DelveInsight’s, “Parkinson’s Disease - Pipeline Insight, 2023,” report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Parkinson’s Disease Understanding

Parkinson’s Disease: Overview

Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Studies have shown that symptoms of Parkinson's develop in patients with an 80 percent or greater loss of dopamine-producing cells in the substantia nigra. Normally, dopamine operates in a delicate balance with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in movement. Without enough dopamine, this balance is disrupted, resulting in tremor (trembling in the hands, arms, legs and jaw); rigidity (stiffness of the limbs); slowness of movement; and impaired balance and coordination – the hallmark symptoms of Parkinson's. The cause of Parkinson's essentially remains unknown. However, theories involving oxidative damage, environmental toxins, and genetic factors and accelerated aging have been discussed as potential causes for the disease. In 2005, researchers discovered a single mutation in a Parkinson’s disease gene (first identified in 1997), which is believed responsible for five percent of inherited cases. The majority of Parkinson's patients are treated with medications to relieve the symptoms of the disease. These medications work by stimulating the remaining cells in the substantia nigra to produce more dopamine (levodopa medications) or by inhibiting some of the acetylcholine that is produced (anticholinergic medications), therefore restoring the balance between the chemicals in the brain.


"Parkinson’s disease - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Parkinson’s disease pipeline landscape is provided which includes the disease overview and Parkinson’s disease treatment guidelines. The assessment part of the report embraces, in depth Parkinson’s disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Parkinson’s disease.    
  • In the coming years, the Parkinson’s disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Parkinson’s disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Parkinson’s disease treatment market. Several potential therapies for Parkinson’s disease are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Parkinson’s disease market size in the coming years.  
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Parkinson’s disease) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Parkinson’s disease Emerging Drugs Chapters

This segment of the Parkinson’s disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Parkinson’s disease Emerging Drugs


Tavapadon: Cerevel Therapeutics

Tavapadon was designed to improve motor symptoms in Parkinson’s disease by selectively targeting and binding to dopamine D1/D5 receptor subtypes. Tavapadon differentially activates the direct motor pathway, potentially driving motor benefit while minimizing side effects typical of drugs that non-selectively stimulate dopamine, such as daytime sedation, or somnolence, compromised impulse control and risk of psychotic symptoms including hallucinations.  Tavapadon is also designed to activate the D1/D5 receptor subtypes at levels that maximize motor benefit while reducing the prolonged receptor overexcitation and desensitization caused by full agonists, which can lead to dyskinesias and exacerbation of “off” time. Currently, it is in Phase III stage of clinical trial evaluation to treat Parkinson disease.


IkT-148009: Inhibikase Therapeutics

Inhibikase Therapeutics’ lead product candidate, IkT-148009, is a potent, selective small-molecule medication designed and engineered as chronically administered, once-daily oral medication targeting the underlying biological mechanism resulting in Parkinson’s disease, with the goal of halting disease progression and reversing functional loss. IkT-148009 is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms. 


NLY01: Neuraly

NLY01 is a proprietary long-acting analogue of exendin-4, a glucagon-like peptide-1 receptor (GLP-1R) agonist. NLY01 penetrates the blood-brain barrier (BBB) in animal models and its receptor (GLP-1R) is highly expressed on glial cells. NLY01 is being developed as a disease-modifying agent for neurodegenerative disorders including Parkinson’s and Alzheimer’s disease. In clinically relevant animal models, NLY01 was found to prevent neuronal cell death by inhibition of microglial activation and formation of A1 neurotoxic astroglial cells. Treatment with NLY01 slowed disease progression, improved motor and cognitive functions and extended the lifespan in mice with Parkinson’s disease.


PT320: Peptron

PT320 is a sustained-release Exenatide (GLP1 agonist) for biweekly injection (Q2W). Due to its short half-life of 2.4 hours in the plasma of Exenatide, Peptron has developed a long-acting SR-Exenatide (PT320), resulting in sustained elevations of Exenatide for 20 days. With the result of preclinical and Phase I study of PT320, Peptron is testing the efficacy of PT320 of Parkinson's disease in the on-going Phase II trial.
Further product details are provided in the report……..

Parkinson’s disease: Therapeutic Assessment

This segment of the report provides insights about the different Parkinson’s disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Parkinson’s disease

There are approx. 140+ key companies which are developing the therapies for Parkinson’s disease. The companies which have their Parkinson’s disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics.



DelveInsight’s report covers around 150+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates


Route of Administration

Parkinson’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous


Molecule Type

Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine


Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Parkinson’s Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Parkinson’s Disease therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Parkinson’s Disease drugs.

Parkinson’s Disease Report Insights

  • Parkinson’s Disease Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Parkinson’s Disease Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Parkinson’s Disease drugs?
  • How many Parkinson’s Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Parkinson’s Disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Parkinson’s Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Parkinson’s Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?


Executive Summary

Parkinson’s Disease: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Parkinson’s Disease – DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

Tavapadon: Cerevel Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Prasinezumab : Roche

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

MEDI1341: AstraZeneca

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Neural microtissues: Treefrog Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Parkinson’s Disease Key Companies

Parkinson’s Disease Key Products

Parkinson’s Disease- Unmet Needs

Parkinson’s Disease- Market Drivers and Barriers

Parkinson’s Disease- Future Perspectives and Conclusion

Parkinson’s Disease Analyst Views

Parkinson’s Disease Key Companies


List of Table

Table 1: Total Products for Parkinson’s Disease

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Parkinson’s Disease

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Cerevel Therapeutics
• Inhibikase Therapeutics
• Neuraly
• Peptron
• Biogen
• Roche
• Brain Neurotherapy Bio, Inc.
• Modag
• Annovis Bio Inc.
• BioVie Inc.
• United Neuroscience Ltd.
• Luye Pharma Group
• AbbVie
• UCB Biopharma SRL
• InnoMedica Schweiz AG
• Integrative Research Laboratories AB
• H. Lundbeck A/S
• Shanghai WD Pharmaceutical Co., Ltd.
• Cerevance Beta, Inc.
• Nobilis Therapeutics Inc.
• BlueRock Therapeutics
• Taiwan Mitochondrion Applied Technology Co., Ltd.
• NeuroDerm Ltd.
• Pharma Two B
• Serina Therapeutics
• Sun Pharma Advanced Research Company Limited
• CuraSen Therapeutics, Inc.
• Takeda
• Xoc Pharmaceuticals
• Sumitomo Pharma Co., Ltd.
• XWPharma
• Athira Pharma
• Aptinyx
• VistaGen Therapeutics, Inc.
• 1ST Biotherapeutics, Inc.
• Novo Nordisk A/S
• AstraZeneca
• MedImmune
• Anavex Life Sciences Corp.
• Living Cell Technologies
• Intra-Cellular Therapies, Inc.
• Alkahest, Inc.
• Kissei Pharmaceutical Co., Ltd.

Forward to Friend

Need A Quote